AstraZeneca (STU:ZEGA) Common Stock: €336 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEGA AstraZeneca PLC STU:ZEGA
88 GF Score
Price €78.00
GF Value €83.11
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Common Stock?

AstraZeneca STU:ZEGA +1.30% 88 Common Stock is €336 Mil as of Mar. 2026. GuruFocus rates STU:ZEGA with a GF Score™ of 88/100 and a GF Value™ of €83.11. The stock has 1 warning sign investors should review.

AstraZeneca's quarterly common stock increased from Sep. 2025 (€331 Mil) to Dec. 2025 (€331 Mil) and increased from Dec. 2025 (€331 Mil) to Mar. 2026 (€336 Mil).

AstraZeneca's annual common stock increased from Dec. 2023 (€356 Mil) to Dec. 2024 (€371 Mil) but then declined from Dec. 2024 (€371 Mil) to Dec. 2025 (€331 Mil).

AstraZeneca Common Stock Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Common Stock Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 342.50 365.33 355.80 370.54 331.35

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 358.90 336.40 330.58 331.35 335.62
STU:ZEGA
88GF Score
AstraZeneca PLC STU:ZEGA
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €336 Mil mean?
AstraZeneca (STU:ZEGA) has a Common Stock of €336 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Common Stock too high?
AstraZeneca's current Common Stock is €336 Mil. Overall, AstraZeneca has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Common Stock compare to LLY and JNJ?
AstraZeneca's Common Stock of €336 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on AstraZeneca and its competitors. AstraZeneca's current Common Stock is €336 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (STU:ZEGA) has a current Common Stock of €336 Mil. The stock's GF Value™ is €83.11, compared to a current price of €78.00 — trading 6.1% below its estimated fair value. The current Common Stock is €336 Mil. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For AstraZeneca (STU:ZEGA), the current Common Stock is €336 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €78.00 is trading 6.1% below its estimated GF Value™ of €83.11.

Key valuation signals for STU:ZEGA:

  • Common Stock: €336 Mil
  • GF Value™: €83.11 vs. price of €78.00 (6.1% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for STU:ZEGA

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€83.11
GF Value